Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Simulations Plus share price

Simulations Plus, Inc. · SLP · Healthcare · Health Information Services · last close in our records 5 October 2026 · results updated weekly · All US stock lists

Simulations Plus share price: $18.50 at the close on 5 October 2026, the latest close in our records, +15.5% in a year.

Getting worseBusiness trend from the last 12 quarters
$18.50Price +15.5% in a year
46.3×P/E over 1 year
$21.9 MRevenue (May 2026) +7.5% on a year ago
$3.6 MProfit (May 2026)
22.8%Operating margin +8.1 points on a year ago
−52%ROE FY25
8.9%ROIC against a 11.5% cost of capital: −2.6 points

Simulations Plus, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer.

The main question: the share price moved +15.5% in a year while yearly earnings per share moved −757.1%. The difference came from the market paying a higher multiple.

The price has been between phases. Over the last four quarters, results have been improving, and 164% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.

What is the Simulations Plus share price?

Simulations Plus, Inc.'s share price was $18.50 at the close on 5 October 2026. That is 13.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $11 and $21, and at that close it sat 75% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 4 weeks running.

Oct 2026: $18.50, 13.1% above its 200-day average.

  • Price $18.50
  • 50-day avg $18.39
  • 200-day avg $16.35
Oct 2026: $18.50, 13.1% above its 200-day average.
WeekPrice50-day avg200-day avg
11 Jul 2025$16.96––
18 Jul 2025$12.46––
25 Jul 2025$13.23––
1 Aug 2025$12.80––
8 Aug 2025$14.17––
15 Aug 2025$14.24––
22 Aug 2025$14.57––
29 Aug 2025$14.17––
5 Sep 2025$13.84––
12 Sep 2025$15.05––
19 Sep 2025$15.25$14.04–
26 Sep 2025$14.89$14.07–
3 Oct 2025$16.02$14.31–
10 Oct 2025$14.76$14.58–
17 Oct 2025$15.40$14.82–
24 Oct 2025$17.83$15.09–
31 Oct 2025$17.18$15.45–
7 Nov 2025$17.13$15.75–
14 Nov 2025$17.31$16.07–
21 Nov 2025$17.00$16.30–
28 Nov 2025$17.00$16.44–
5 Dec 2025$19.64$16.89–
12 Dec 2025$19.17$17.32–
19 Dec 2025$18.75$17.58–
26 Dec 2025$18.76$17.89–
2 Jan 2026$18.11$18.09–
9 Jan 2026$19.60$18.21–
16 Jan 2026$20.33$18.47–
23 Jan 2026$20.84$18.73–
30 Jan 2026$16.89$18.86–
6 Feb 2026$14.57$18.70–
13 Feb 2026$12.29$18.25–
20 Feb 2026$11.66$17.61–
27 Feb 2026$12.23$16.84–
6 Mar 2026$12.22$16.18–
13 Mar 2026$12.44$15.54–
20 Mar 2026$11.67$14.85–
27 Mar 2026$11.42$14.08–
2 Apr 2026$11.99$13.40–
10 Apr 2026$13.04$12.69–
17 Apr 2026$14.37$12.44–
24 Apr 2026$14.56$12.54$15.39
1 May 2026$14.91$12.77$15.36
8 May 2026$16.68$13.19$15.44
15 May 2026$13.34$13.35$15.45
22 May 2026$15.37$13.57$15.49
29 May 2026$17.11$13.90$15.53
5 Jun 2026$15.88$14.40$15.59
12 Jun 2026$16.32$14.84$15.64
18 Jun 2026$18.24$15.26$15.71
26 Jun 2026$18.20$15.74$15.81
2 Jul 2026$18.39$16.03$15.89
10 Jul 2026$18.24$16.39$15.96
17 Jul 2026$18.23$16.74$16.05
24 Jul 2026$18.34$17.02$16.11
31 Jul 2026$18.23$17.49$16.17
7 Aug 2026$18.32$17.80$16.24
14 Aug 2026$18.35$17.95$16.27
21 Aug 2026$18.40$18.18$16.29
28 Aug 2026$18.39$18.30$16.32
4 Sep 2026$18.43$18.33$16.34
11 Sep 2026$18.42$18.34$16.38
18 Sep 2026$18.44$18.35$16.41
25 Sep 2026$18.46$18.37$16.38
2 Oct 2026$18.50$18.39$16.35
5 Oct 2026$18.50$18.39$16.35
Weekly closing price ($) with its 50-day and 200-day averages. 1-year window.

Week by week since 2025: did it beat the S&P 500 over the past 13 weeks?

Ahead in 34 of 53 weeks

Week by week since 2025: did it beat the S&P 500 over the past 13 weeks?
Week13-week return vs S&P 500
11 Jul 2025no S&P 500 reading
18 Jul 2025no S&P 500 reading
25 Jul 2025no S&P 500 reading
1 Aug 2025no S&P 500 reading
8 Aug 2025no S&P 500 reading
15 Aug 2025no S&P 500 reading
22 Aug 2025no S&P 500 reading
29 Aug 2025no S&P 500 reading
5 Sep 2025no S&P 500 reading
12 Sep 2025no S&P 500 reading
19 Sep 2025no S&P 500 reading
26 Sep 2025no S&P 500 reading
3 Oct 2025no S&P 500 reading
10 Oct 2025−17.7%
17 Oct 2025+17.7%
24 Oct 2025+28.5%
31 Oct 2025+24.5%
7 Nov 2025+15.6%
14 Nov 2025+17.1%
21 Nov 2025+14.6%
28 Nov 2025+14.0%
5 Dec 2025+36.0%
12 Dec 2025+23.7%
19 Dec 2025+20.4%
26 Dec 2025+21.7%
2 Jan 2026+11.0%
9 Jan 2026+26.5%
16 Jan 2026+27.9%
23 Jan 2026+15.1%
30 Jan 2026−3.1%
6 Feb 2026−17.9%
13 Feb 2026−30.5%
20 Feb 2026−36.0%
27 Feb 2026−28.4%
6 Mar 2026−35.8%
13 Mar 2026−32.3%
20 Mar 2026−33.1%
27 Mar 2026−31.0%
2 Apr 2026−29.8%
10 Apr 2026−31.4%
17 Apr 2026−32.0%
24 Apr 2026−33.7%
1 May 2026−15.9%
8 May 2026+7.7%
15 May 2026+0.1%
22 May 2026+23.7%
29 May 2026+29.6%
5 Jun 2026+20.3%
12 Jun 2026+19.2%
18 Jun 2026+41.2%
26 Jun 2026+44.4%
2 Jul 2026+39.8%
10 Jul 2026+28.8%
17 Jul 2026+22.2%
24 Jul 2026+22.5%
31 Jul 2026+18.6%
7 Aug 2026+5.0%
14 Aug 2026+32.5%
21 Aug 2026+17.0%
28 Aug 2026+5.8%
4 Sep 2026+11.6%
11 Sep 2026+9.8%
18 Sep 2026−0.9%
25 Sep 2026−4.4%
2 Oct 2026−2.7%
5 Oct 2026−0.5%
Each bar is one week, from 2025 to now (53 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the S&P 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 1 year the share price moved +9% while the S&P 500 moved +23%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What dividend does Simulations Plus pay?

Simulations Plus, Inc. paid $0.24 per share over the last four reported quarters. The most recent declaration was $0.06 for Aug 2024. At today's price of $18.50 that is a yield of 1.30%, based on dividends already paid, not a forecast.

A dividend is cash paid out for each share. The 12-month total is the four most recent quarters added together.

Dividend per share each quarter: latest $0.06 (Aug 2024)

  • Dividend per share $0.06
Dividend per share each quarter: latest $0.06 (Aug 2024)
QuarterDividend per share
Aug 2023$0.06
Nov 2023$0.06
Feb 2024$0.06
May 2024$0.06
Aug 2024$0.06
Declared dividend per share, $ a share, each reported quarter. 5 quarters on file.

Which stock lists is Simulations Plus on?

Simulations Plus is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Is Simulations Plus profitable?

Simulations Plus, Inc. earned $3.6 M of net profit in the May 2026 quarter. The full FY25 year was a loss of $64.7 M. That is 16.3% of the quarter's revenue. The same quarter a year earlier lost $67.3 M. 2 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was −$64.7 M (−750.2% on the year before).

FY25 profit −$64.7 M (−750.2% on the year before)

  • Net profit −$64.7 M
FY25 profit −$64.7 M (−750.2% on the year before)
QuarterNet profit
FY21$9.8 M
FY22$12.5 M
FY23$10.0 M
FY24$10.0 M
FY25−$64.7 M

Growth on a year earlier

  • Growth on a year earlier −750.2%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY2227.6%
FY23−20.2%
FY24−0.1%
FY25−750.2%
Top: net profit each year, $ M. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

May 2026: $3.6 M

  • Net profit (quarterly) $3.6 M
May 2026: $3.6 M
QuarterNet profit (quarterly)
Aug 2023$0.5 M
Nov 2023$1.9 M
Feb 2024$4.0 M
May 2024$3.1 M
Aug 2024$0.8 M
Nov 2024$0.2 M
Feb 2025$3.1 M
May 2025−$67.3 M
Aug 2025−$0.7 M
Nov 2025$0.7 M
Feb 2026$4.5 M
May 2026$3.6 M

Growth on a year earlier

  • Growth on a year earlier 47.5%
Growth on a year earlier
QuarterGrowth on a year earlier
Aug 2023−44.4%
Nov 202356.2%
Feb 2024−3.5%
May 2024−21.7%
Aug 202457.9%
Nov 2024−89.4%
Feb 2025−23.7%
May 2025−2,245.9%
Aug 2025−180.8%
Nov 2025228.2%
Feb 202647.5%
May 2026–
Top: net profit each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

On average over the last four quarters, profit changed +31.6% and revenue +1.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

How much revenue does Simulations Plus make, and is it growing?

Simulations Plus, Inc. reported $21.9 M of revenue in the May 2026 quarter, +7.5% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 14.3% a year on average. The last full year, FY25, came in at $79.2 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $82.1 M.

FY25 revenue was $79.2 M, +13.1% on the year before.

FY25 revenue $79.2 M (+13.1% on the year before), 14.3% a year over 4 years

  • Revenue $79.2 M
FY25 revenue $79.2 M (+13.1% on the year before), 14.3% a year over 4 years
QuarterRevenue
FY21$46.5 M
FY22$53.9 M
FY23$59.6 M
FY24$70.0 M
FY25$79.2 M

Growth on a year earlier

  • Growth on a year earlier 13.1%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY2216%
FY2310.5%
FY2417.5%
FY2513.1%
Top: revenue each year, $ M. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

May 2026: $21.9 M (+7.5% on a year earlier), the 2nd quarter in a row of growth

  • Revenue (quarterly) $21.9 M
May 2026: $21.9 M (+7.5% on a year earlier), the 2nd quarter in a row of growth
QuarterRevenue (quarterly)
Aug 2023$15.6 M
Nov 2023$14.5 M
Feb 2024$18.3 M
May 2024$18.5 M
Aug 2024$18.7 M
Nov 2024$18.9 M
Feb 2025$22.4 M
May 2025$20.4 M
Aug 2025$17.5 M
Nov 2025$18.4 M
Feb 2026$24.3 M
May 2026$21.9 M

Growth on a year earlier

  • Growth on a year earlier 7.5%
Growth on a year earlier
QuarterGrowth on a year earlier
Aug 202333.2%
Nov 202321.2%
Feb 202416.2%
May 202414.2%
Aug 202419.4%
Nov 202430.5%
Feb 202522.5%
May 20259.8%
Aug 2025−6.5%
Nov 2025−2.7%
Feb 20268.3%
May 20267.5%
Top: revenue each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Recent pace: the last four quarters grew +1.7% on average, against 14.3% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +2.1%, against +10.7% a year over the last 8 quarters (rolling over).

How much of every $100 of sales does Simulations Plus keep?

Simulations Plus, Inc.'s operating margin was 22.8% in the May 2026 quarter, 8.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between 9.1% and 28.2%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +8.1 percentage points on the year while gross margin changed +5.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY25: 9.1%, within a range of 9.1% to 28.2% over 5 years

  • Operating margin 9.1%
FY25: 9.1%, within a range of 9.1% to 28.2% over 5 years
QuarterOperating margin
FY2124.2%
FY2228.2%
FY2321%
FY2412.5%
FY259.1%

Change on the year before (points)

  • Change on the year before (points) −3.4 pts
Change on the year before (points)
QuarterChange on the year before (points)
FY21–
FY22+4.0 pts
FY23−7.2 pts
FY24−8.5 pts
FY25−3.4 pts
Operating margin each year, % (top). Below: change on the year before, in percentage points. 5-year window.

May 2026: operating margin 22.8% (+8.1 points on a year earlier)

  • Operating margin 22.8%
May 2026: operating margin 22.8% (+8.1 points on a year earlier)
QuarterOperating margin
Aug 202322.5%
Nov 20236.6%
Feb 202424.3%
May 202415%
Aug 20242.9%
Nov 20242.3%
Feb 202511.6%
May 202514.7%
Aug 20253.2%
Nov 20253.9%
Feb 202623.2%
May 202622.8%

Change on a year earlier (points)

  • Change on a year earlier (points) +8.1 pts
Change on a year earlier (points)
QuarterChange on a year earlier (points)
Aug 2023+14.0 pts
Nov 2023−0.7 pts
Feb 2024−1.3 pts
May 2024−10.2 pts
Aug 2024−19.6 pts
Nov 2024−4.3 pts
Feb 2025−12.7 pts
May 2025−0.3 pts
Aug 2025+0.3 pts
Nov 2025+1.6 pts
Feb 2026+11.6 pts
May 2026+8.1 pts
Top: quarterly operating margin, %. Below: change on the same quarter a year earlier, in percentage points. Last 12 quarters. Operating profit as a share of revenue, each quarter.

Is Simulations Plus' profit turning into cash?

Over the last 3 years, 164% of Simulations Plus, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $18.1 M of operating cash against −$64.7 M of profit. After $713 K of spending on assets, $17.4 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

FY25: operating cash $18.1 M against profit −$64.7 M; 164% of 3 years' profit came in as cash

  • Operating cash $18.1 M
  • Net profit −$64.7 M
  • Free cash $17.4 M
FY25: operating cash $18.1 M against profit −$64.7 M; 164% of 3 years' profit came in as cash
QuarterOperating cashNet profitFree cash
FY21$19.2 M$9.8 M$17.6 M
FY22$17.9 M$12.5 M$17.1 M
FY23$21.9 M$10.0 M$21.4 M
FY24$13.3 M$10.0 M$12.8 M
FY25$18.1 M−$64.7 M$17.4 M
Operating cash flow and net profit each year, $ M. The line is free cash flow: operating cash minus spending on assets. 5-year window, yearly figures.

May 2026: operating cash $8.7 M = 244% of the quarter's profit

  • Operating cash (quarterly) $8.7 M
May 2026: operating cash $8.7 M = 244% of the quarter's profit
QuarterOperating cash (quarterly)
Aug 2023$3.1 M
Nov 2023$0.2 M
Feb 2024$5.8 M
May 2024$5.7 M
Aug 2024$1.7 M
Nov 2024−$1.3 M
Feb 2025$5.7 M
May 2025$8.1 M
Aug 2025$5.6 M
Nov 2025$4.2 M
Feb 2026$6.4 M
May 2026$8.7 M

Operating cash as % of profit

  • Operating cash as % of profit 244%
Operating cash as % of profit
QuarterOperating cash as % of profit
Aug 2023573%
Nov 20238%
Feb 2024144%
May 2024181%
Aug 2024197%
Nov 2024−618%
Feb 2025184%
May 2025–
Aug 2025–
Nov 2025626%
Feb 2026141%
May 2026244%
Top: operating cash each quarter, $ M. Below: operating cash as a % of net profit; 100% means all of the quarter's profit came in as cash. Last 12 quarters.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Where does Simulations Plus' cash go?

Simulations Plus, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.7 M on assets over the last 3 years. Averaged over those years that is 0.7% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $1.7 M over the last 3 years.

FY25: capex $0.7 M, steady spending

  • Capex $0.7 M
FY25: capex $0.7 M, steady spending
QuarterCapex
FY21$1.6 M
FY22$0.8 M
FY23$0.5 M
FY24$0.6 M
FY25$0.7 M
Capital spending each year, $ M.

May 2026: capex $0.1 M in the quarter

  • Capex (quarterly) $0.1 M
May 2026: capex $0.1 M in the quarter
QuarterCapex (quarterly)
Feb 2023$0.2 M
May 2023$0.1 M
Aug 2023$0.2 M
Feb 2024$0.4 M
May 2024$0.1 M
Aug 2024$0
Nov 2024$0.1 M
Feb 2025$0.1 M
May 2025$0.3 M
Aug 2025$0.3 M
Feb 2026$0
May 2026$0.1 M

Free cash

  • Free cash $8.6 M
Free cash
QuarterFree cash
Feb 2023$5.3 M
May 2023$8.6 M
Aug 2023$2.9 M
Feb 2024$5.4 M
May 2024$5.6 M
Aug 2024$1.6 M
Nov 2024−$1.4 M
Feb 2025$5.6 M
May 2025$7.8 M
Aug 2025$5.3 M
Feb 2026$6.4 M
May 2026$8.6 M
Top: capital spending each quarter, $ M. Below: free cash flow, $ M. Last 12 quarters.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

What is Simulations Plus' P/E ratio, and how does it compare with its own history?

Simulations Plus, Inc.'s P/E is 46.3×, with too little history to compare. Its usual P/E (the middle reading) is 46.4×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

P/E 46.3× against a usual 46.4×: with too little history to compare

  • P/E 47.1×
  • Median 46.4×
P/E 46.3× against a usual 46.4×: with too little history to compare
WeekP/EMedian
11 Jul 202548.6×46.4×
18 Jul 202535.7×46.4×
25 Jul 202537.9×46.4×
1 Aug 202536.7×46.4×
8 Aug 202540.6×46.4×
15 Aug 202540.8×46.4×
22 Aug 202541.8×46.4×
29 Aug 202540.6×46.4×
5 Sep 202539.7×46.4×
12 Sep 202543.1×46.4×
19 Sep 202543.7×46.4×
26 Sep 202542.7×46.4×
3 Oct 202545.9×46.4×
5 Jun 202640.4×46.4×
12 Jun 202641.5×46.4×
18 Jun 202646.4×46.4×
26 Jun 202646.3×46.4×
2 Jul 202646.8×46.4×
10 Jul 202646.4×46.4×
17 Jul 202646.4×46.4×
24 Jul 202646.7×46.4×
31 Jul 202646.4×46.4×
7 Aug 202646.6×46.4×
14 Aug 202646.7×46.4×
21 Aug 202646.8×46.4×
28 Aug 202646.8×46.4×
4 Sep 202646.9×46.4×
11 Sep 202646.9×46.4×
18 Sep 202646.9×46.4×
25 Sep 202647.0×46.4×
2 Oct 202647.1×46.4×
5 Oct 202647.1×46.4×

Earnings per share, 12 months

  • Earnings per share, 12 months $0.39
Earnings per share, 12 months
WeekEarnings per share, 12 months
11 Jul 2025–
18 Jul 2025–
25 Jul 2025–
1 Aug 2025–
8 Aug 2025–
15 Aug 2025–
22 Aug 2025–
29 Aug 2025–
5 Sep 2025–
12 Sep 2025–
19 Sep 2025–
26 Sep 2025$0.35
3 Oct 2025$0.35
5 Jun 2026$0.35
12 Jun 2026$0.35
18 Jun 2026$0.35
26 Jun 2026$0.39
2 Jul 2026$0.39
10 Jul 2026$0.39
17 Jul 2026$0.39
24 Jul 2026$0.39
31 Jul 2026$0.39
7 Aug 2026$0.39
14 Aug 2026$0.39
21 Aug 2026$0.39
28 Aug 2026$0.39
4 Sep 2026$0.39
11 Sep 2026$0.39
18 Sep 2026$0.39
25 Sep 2026$0.39
2 Oct 2026$0.39
5 Oct 2026$0.39
Top: P/E each week. Below: earnings per share, trailing twelve months, a step line that moves once a quarter; 1 year of history.

PEG 3.14 at the May 2026 quarter end: above 1.0, so the P/E is bigger than the earnings growth rate

  • PEG 3.14×
  • PEG = 1.0 1.00×
PEG 3.14 at the May 2026 quarter end: above 1.0, so the P/E is bigger than the earnings growth rate
QuarterPEGPEG = 1.0
Aug 20215.37×1.00×
Nov 20215.64×1.00×
Feb 20223.88×1.00×
May 20224.28×1.00×
Aug 20224.90×1.00×
Nov 20223.62×1.00×
Feb 20233.36×1.00×
May 20233.61×1.00×
Aug 20234.20×1.00×
Nov 20233.92×1.00×
Feb 20243.97×1.00×
May 20244.41×1.00×
Aug 20244.90×1.00×
Nov 20242.77×1.00×
Feb 20253.49×1.00×
May 20253.14×1.00×
Aug 20253.14×1.00×
Nov 20253.14×1.00×
Feb 20263.14×1.00×
May 20263.14×1.00×
PEG each quarter: the P/E divided by the yearly growth rate of earnings. The flat line marks 1.0. Below it the P/E is smaller than the growth rate; above it the P/E is bigger. Last 20 quarters.
46.3×P/E · too little history to compare
48.26PEG · today, derived from 3-year earnings growth

Why the multiple is where it is: over the past year earnings per share moved −757.1% while the price moved +15.5%. The price did better than earnings, which pushed the multiple up within its own range.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Is the Simulations Plus business getting better or worse?

Simulations Plus, Inc.'s business is getting worse. Profit and EPS growth are shrinking: profit growth is −964.8% in the latest quarter, against +0.5% at its best in 12 quarters, with ROCE steady at 9.0%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Growth year by year: revenue +13.1% in FY25, profit −750.2%

  • Revenue growth 13.1%
Growth year by year: revenue +13.1% in FY25, profit −750.2%
QuarterRevenue growth
FY21–
FY2216%
FY2310.5%
FY2417.5%
FY2513.1%

Profit growth, EPS growth

  • Profit growth −300%
  • EPS growth −300%
Profit growth, EPS growth
QuarterProfit growthEPS growth
FY21––
FY2227.6%27.7%
FY23−20.2%−18.3%
FY24−0.1%0%
FY25−300%−300%
Growth on the year before, each year, %. Top: revenue. Below: net profit and earnings per share, on their own scale because profit growth swings much more. Zero line drawn. Turnaround-year jumps are drawn at the edge (▲).

Three growth lines over twelve quarters: revenue rolling over

  • Revenue 2.1%
Three growth lines over twelve quarters: revenue rolling over
QuarterRevenue
Aug 202310.5%
Nov 202316.2%
Feb 202418.9%
May 202420.3%
Aug 202417.5%
Nov 202419.8%
Feb 202521.5%
May 202520%
Aug 202513.1%
Nov 20255.7%
Feb 20262.5%
May 20262.1%

Profit, EPS

  • Profit −300%
  • EPS −300%
Profit, EPS
QuarterProfitEPS
Aug 2023−20.2%−19%
Nov 2023−0.4%2.6%
Feb 20240.5%4.7%
May 2024−7.2%−5.3%
Aug 2024−0.1%0.2%
Nov 2024−22.9%−23.7%
Feb 2025−31%−33.3%
May 2025−300%−300%
Aug 2025−300%−300%
Nov 2025−300%−300%
Feb 2026−300%−300%
May 2026––
Growth on a year earlier, % at each quarter end. Top: revenue. Below: profit and earnings per share, on their own scale because they swing much more. Each is measured over the last 12 months. Extreme jumps from a tiny base are drawn at the edge (▲). A gap means there is no reading for that quarter.

ROCE: the return line, worked out each quarter

  • ROCE 9%
ROCE: the return line, worked out each quarter
QuarterROCE
Aug 20237.1%
Nov 20237%
Feb 20247.5%
May 20246.7%
Aug 20244.9%
Nov 20244.5%
Feb 20253.4%
May 2025–
Aug 2025–
Nov 2025–
Feb 2026–
May 20269%
Operating profit over the last 12 months (before interest and tax) as a share of average capital employed (total assets minus current liabilities), %.
FallingRevenue growth · latest +2.1%, range +2.1% to +21.5%
FallingProfit growth · latest −964.8%, range −964.8% to +0.5%
FallingEPS growth · latest −996.7%, range −996.7% to +4.7%
Stuck lowROCE · latest 9.0%, range 3.4% to 9.0%

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+13.1%+13.7%——
Stock price+15.5%———
+7.5%Revenue growth (May 2026) · latest quarter against a year ago
14.3%Revenue, 4 years · yearly growth over the long run

How much does Simulations Plus earn on its capital?

Simulations Plus, Inc. earned a ROE of −52% in FY25. Its return on capital used (ROIC) is 2.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −81.7% net margin and 0.60× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a −81.7% net margin × 0.60× asset turnover × 1.06× leverage (assets divided by equity) ≈ −52.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 8.9% − 11.5% = −2.6 percentage points. The 11.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 8.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 5.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

FY25: ROE −52%, the full history

  • ROE −51.9%
  • ROIC (annual) 5.6%
  • Cost of capital 11.5%
FY25: ROE −52%, the full history
QuarterROEROIC (annual)Cost of capital
FY215.9%23.5%11.5%
FY227%26.5%11.5%
FY235.9%19.9%11.5%
FY245.5%6.4%11.5%
FY25−51.9%5.6%11.5%
Return on equity each year, % (line); ROIC each year, % (line). 5-year window, low years included. The flat line is the 11.5% cost of capital used on this page.

May 2026: ROIC 4.7% (last 12 months) against a 11.5% cost of capital

  • ROIC (12 months) 4.7%
  • ROE (12 months) 13.9%
  • Cost of capital 11.5%
May 2026: ROIC 4.7% (last 12 months) against a 11.5% cost of capital
QuarterROIC (12 months)ROE (12 months)Cost of capital
Aug 20236.8%9.6%11.5%
Nov 20236.8%1.3%11.5%
Feb 20241.3%4.5%11.5%
May 20245.3%9.2%11.5%
Aug 20243.4%7%11.5%
Nov 20240.5%1.9%11.5%
Feb 20250.2%0.4%11.5%
May 20251.4%6.6%11.5%
Aug 20252.3%−171.9%11.5%
Nov 2025−0.5%−2.2%11.5%
Feb 20260.5%2.1%11.5%
May 20264.7%13.9%11.5%
ROIC and ROE over the last 12 months, each quarter, %; the flat line is the cost of capital. Last 12 quarters, lined up with the yearly figure.

Does Simulations Plus have too much debt?

Simulations Plus, Inc. has total debt of $487 K against shareholder equity of $139 M as of May 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.00 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

FY25: debt $0.6 M, 0.00× equity

  • Total debt $0.6 M
FY25: debt $0.6 M, 0.00× equity
QuarterTotal debt
FY21$1.3 M
FY22$1.4 M
FY23$1.2 M
FY24$1.0 M
FY25$0.6 M

Debt-to-equity

  • Debt-to-equity 0.00×
Debt-to-equity
QuarterDebt-to-equity
FY210.01×
FY220.01×
FY230.01×
FY240.01×
FY250.00×
Top: total debt each year, $ M. Below: debt-to-equity, ×. 5-year window.

May 2026: debt $0.5 M, debt-to-equity 0.00

  • Total debt (quarterly) $0.5 M
May 2026: debt $0.5 M, debt-to-equity 0.00
QuarterTotal debt (quarterly)
Aug 2023$1.2 M
Nov 2023$1.1 M
Feb 2024$1.0 M
May 2024$0.9 M
Aug 2024$1.0 M
Nov 2024$1.3 M
Feb 2025$0.8 M
May 2025$0.7 M
Aug 2025$0.6 M
Nov 2025$0.6 M
Feb 2026$0.5 M
May 2026$0.5 M

Debt-to-equity

  • Debt-to-equity 0.00×
Debt-to-equity
QuarterDebt-to-equity
Aug 20230.01×
Nov 20230.01×
Feb 20240.01×
May 20240.01×
Aug 20240.01×
Nov 20240.01×
Feb 20250.00×
May 20250.01×
Aug 20250.00×
Nov 20250.00×
Feb 20260.00×
May 20260.00×
Top: total debt each quarter, $ M. Below: debt-to-equity, ×. Last 12 quarters.

What is the Simulations Plus shareholding pattern?

17.2% of Simulations Plus, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 16.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

17.2%Short interest · of the tradable float
16.3Days to cover · at typical volumes

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

How far is Simulations Plus from balance-sheet trouble?

For Simulations Plus, Inc., the Z-score is 14.84. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 14.84 is well clear of the danger zone, so the balance sheet is not the risk here.

How does Simulations Plus rank in its industry?

56.3 out of 100, rank 26 of 29 in Health Information Services, with 44% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Simulations Plus, Inc. scores 56.3 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 26. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 25.1 + 18.9 + 12.3 = 56.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Simulations Plus compared with?

Simulations Plus ranks 26 of 29 Health Information Services companies on the 4-Factor Sector Score, with 56.3 out of 100.

  1. 1Hinge Health, Inc.HNGE · leader · Most evidence points up · 64% evidence72.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.5/35 · Revenue 49.7% · Profit — · Operating margin change 436.5 points · 62% evidenceCapital efficiency 19.0/25 · ROCE 27.1% · Operating margin 19% · 76% evidenceValuation 9.3/20 · P/E 59.8× · PEG — · 15% evidenceRelative strength 17.3/20 · Lead over its industry 40.2% · Lead over S&P 500 78.7% · 1 year 171.7% · 100% evidence · 12 of 12 weeks aheadExact sum: 26.5 + 19 + 9.3 + 17.3 = 72.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  2. 2Veeva Systems Inc.VEEV · breaking out · Most evidence points up · 85% evidence68.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.9/35 · Revenue 16.5% · Profit 25.2% · Operating margin change 0.9 points · 95% evidenceCapital efficiency 18.8/25 · ROCE 13.6% · Operating margin 29.6% · 76% evidenceValuation 13.0/20 · P/E 32.6× · PEG 1.3 · 65% evidenceRelative strength 16.1/20 · Lead over its industry 4% · Lead over S&P 500 34.9% · 1 year 5.3% · 100% evidence · 12 of 12 weeks aheadExact sum: 20.9 + 18.8 + 13 + 16.1 = 68.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 3HeartFlow, Inc.HTFL · leader · Evidence leans up · 61% evidence57.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.0/35 · Revenue 43.2% · Profit — · Operating margin change 3.7 points · 62% evidenceCapital efficiency 4.5/25 · ROCE -24.2% · Operating margin -27.9% · 76% evidenceValuation 10.0/20 · P/E — · PEG — · 0% evidenceRelative strength 19.0/20 · Lead over its industry 22.7% · Lead over S&P 500 57.9% · 1 year 73.7% · 100% evidence · 12 of 12 weeks aheadExact sum: 24 + 4.5 + 10 + 19 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4Waystar Holding Corp.WAY · breaking out · Evidence leans up · 81% evidence56.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.7/35 · Revenue 19.4% · Profit 58.8% · Operating margin change 0.4 points · 83% evidenceCapital efficiency 12.2/25 · ROCE 5.2% · Operating margin 24.4% · 76% evidenceValuation 15.6/20 · P/E 29.2× · PEG 0.64 · 65% evidenceRelative strength 8.7/20 · Lead over its industry -18.4% · Lead over S&P 500 7.6% · 1 year -18% · 100% evidence · 11 of 12 weeks aheadExact sum: 19.7 + 12.2 + 15.6 + 8.7 = 56.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5Schrödinger, Inc.SDGR · leader · Evidence leans up · 64% evidence55.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.0/35 · Revenue 8.8% · Profit — · Operating margin change 26 points · 62% evidenceCapital efficiency 4.6/25 · ROCE -32.9% · Operating margin -70.6% · 76% evidenceValuation 11.2/20 · P/E -22.3× · PEG — · 15% evidenceRelative strength 18.9/20 · Lead over its industry 22.7% · Lead over S&P 500 57.8% · 1 year 60.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 21 + 4.6 + 11.2 + 18.9 = 55.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6HealthEquity, Inc.HQY · turning · Evidence leans up · 85% evidence54.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.4/35 · Revenue 7.4% · Profit 62.3% · Operating margin change 0.5 points · 95% evidenceCapital efficiency 16.1/25 · ROCE 11.4% · Operating margin 28.4% · 76% evidenceValuation 11.6/20 · P/E 35.6× · PEG 1.53 · 65% evidenceRelative strength 5.8/20 · Lead over its industry -14.5% · Lead over S&P 500 12.5% · 1 year 16.1% · 100% evidence · 5 of 12 weeks aheadExact sum: 21.4 + 16.1 + 11.6 + 5.8 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7Doximity, Inc.DOCS · breaking out · Evidence leans up · 81% evidence53.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 11.5/35 · Revenue 11.2% · Profit -28.6% · Operating margin change -16.3 points · 83% evidenceCapital efficiency 20.9/25 · ROCE 21.6% · Operating margin 21.5% · 76% evidenceValuation 10.8/20 · P/E 22.7× · PEG 1.74 · 65% evidenceRelative strength 10.1/20 · Lead over its industry -16.5% · Lead over S&P 500 9.8% · 1 year -36.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 11.5 + 20.9 + 10.8 + 10.1 = 53.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8NRC HealthNRC · turning · Evidence leans up · 64% evidence52.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 9.6/35 · Revenue -0.7% · Profit -68.4% · Operating margin change -24.4 points · 62% evidenceCapital efficiency 18.4/25 · ROCE 24.3% · Operating margin -0.2% · 76% evidenceValuation 9.7/20 · P/E 45× · PEG — · 15% evidenceRelative strength 14.4/20 · Lead over its industry 2.1% · Lead over S&P 500 33.8% · 1 year 84.1% · 100% evidence · 7 of 12 weeks aheadExact sum: 9.6 + 18.4 + 9.7 + 14.4 = 52.1 · What this means: Relative strength against the index is 33.8%, and revenue and profit growth are weak.
  9. 9BrightSpring Health Services, Inc.BTSG · turning · Too little evidence to rank firmly · 56% evidence51.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.0/35 · Revenue — · Profit — · Operating margin change 1.6 points · 39% evidenceCapital efficiency 12.6/25 · ROCE 10.1% · Operating margin 3.4% · 76% evidenceValuation 10.0/20 · P/E 39.7× · PEG — · 15% evidenceRelative strength 9.0/20 · Lead over its industry -2.5% · Lead over S&P 500 27.6% · 1 year 110.6% · 100% evidence · 2 of 12 weeks aheadExact sum: 20 + 12.6 + 10 + 9 = 51.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  10. 10Phreesia, Inc.PHR · turning · Evidence leans down · 67% evidence49.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.7/35 · Revenue 12.7% · Profit — · Operating margin change 7.2 points · 71% evidenceCapital efficiency 9.5/25 · ROCE 4.3% · Operating margin 5.9% · 76% evidenceValuation 9.0/20 · P/E 63.5× · PEG — · 15% evidenceRelative strength 6.8/20 · Lead over its industry -24.7% · Lead over S&P 500 -0.6% · 1 year -40.1% · 100% evidence · 8 of 12 weeks aheadExact sum: 23.7 + 9.5 + 9 + 6.8 = 49 · What this means: Earnings are strong; relative strength in its sector is -24.7% and the one-year return is -40.1%.
  11. 11Tempus AI, Inc.TEM · breaking out · Evidence leans down · 64% evidence48.5out of 100GrowthCapitalValuationRelative
  12. 12Certara, Inc.CERT · leader · Evidence leans down · 64% evidence46.0out of 100GrowthCapitalValuationRelative
  13. 13HealthStream, Inc.HSTM · leader · Evidence leans down · 81% evidence45.6out of 100GrowthCapitalValuationRelative
  14. 14Omada Health, Inc.OMDA · quiet · Evidence leans down · 64% evidence45.2out of 100GrowthCapitalValuationRelative
  15. 1510x Genomics, Inc.TXG · leader · Evidence leans down · 64% evidence45.2out of 100GrowthCapitalValuationRelative
  16. 16American Well CorporationAMWL · losing its lead · Evidence leans down · 61% evidence45.1out of 100GrowthCapitalValuationRelative
  17. 17Spok Holdings, Inc.SPOK · turning · Evidence leans down · 81% evidence44.6out of 100GrowthCapitalValuationRelative
  18. 18Omnicell, Inc.OMCL · turning · Evidence leans down · 71% evidence43.3out of 100GrowthCapitalValuationRelative
  19. 19Carlsmed, Inc.CARL · leader · Evidence leans down · 61% evidence43.1out of 100GrowthCapitalValuationRelative
  20. 20Teladoc Health, Inc.TDOC · turning · Evidence leans down · 61% evidence43.1out of 100GrowthCapitalValuationRelative
  21. 21Privia Health Group, Inc.PRVA · turning · Evidence leans down · 81% evidence42.3out of 100GrowthCapitalValuationRelative
  22. 22Evolent Health, Inc.EVH · turning · Evidence leans down · 64% evidence38.0out of 100GrowthCapitalValuationRelative
  23. 23Claritev CorporationCTEV · quiet · Evidence leans down · 64% evidence37.4out of 100GrowthCapitalValuationRelative
  24. 24SOPHiA GENETICS SASOPH · losing its lead · Evidence leans down · 61% evidence36.4out of 100GrowthCapitalValuationRelative
  25. 25GoodRx Holdings, Inc.GDRX · losing its lead · Most evidence points down · 81% evidence34.9out of 100GrowthCapitalValuationRelative
  26. 26Simulations Plus, Inc. this pageSLP · Too little evidence to rank firmly · 44% evidence56.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.1/43.75 · Revenue 1.3% · Profit — · Operating margin change 8.1 points · 62% evidenceCapital efficiency 18.9/31.25 · ROCE 8.5% · Operating margin 22.8% · 76% evidenceValuation 12.3/25 · P/E 42.7× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 25.1 + 18.9 + 12.3 = 56.3 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  27. 27Talkspace, Inc.TALK · Too little evidence to rank firmly · 44% evidence48.4out of 100GrowthCapitalValuationRelative
  28. 28Weave Communications, Inc.WEAV · Too little evidence to rank firmly · 41% evidence47.7out of 100GrowthCapitalValuationRelative
  29. 29TruBridge, Inc.TBRG · Too little evidence to rank firmly · 31% evidence42.2out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Health Information Services, all 29 compared on one page.

Which companies are close to Simulations Plus in size?

Simulations Plus is the 26th largest of 30 Health Information Services companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Evolent Health, Inc., Carlsmed, Inc. and TruBridge, Inc. Just below it: Claritev Corporation, Spok Holdings, Inc. and American Well Corporation.

Health Information Services companies close in size

  1. Evolent Health, Inc. $543 million
  2. Carlsmed, Inc. $439 million
  3. TruBridge, Inc. $388 million
  4. Simulations Plus, Inc. $374 million
  5. Claritev Corporation $367 million
  6. Spok Holdings, Inc. $253 million
  7. American Well Corporation $210 million

All 30 Health Information Services companies, largest first

Companies close in size in other industries

  1. mF International Limited $376 million · Software - Application
  2. Fennec Pharmaceuticals Inc. $375 million · Biotechnology
  3. Simulations Plus, Inc. $374 million
  4. Cerence Inc. $374 million · Software - Application
  5. Advantage Solutions Inc. $374 million · Advertising Agencies

What else do people ask about Simulations Plus?

What were Simulations Plus's latest quarterly results?

Simulations Plus, Inc. reported revenue of $21.9 M and net profit of $3.6 M for the May 2026 quarter. Earnings per share were $0.18. The operating margin was 22.8%, 8.1 percentage points higher than a year earlier (as of 5 October 2026).

What is Simulations Plus's market cap?

Simulations Plus, Inc.'s market capitalisation is $374 M at a stock price of $18.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 October 2026).

How is Simulations Plus performing?

Simulations Plus, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 4 weeks running. This describes what the data did, not a rating (as of 5 October 2026).

Will Simulations Plus's stock price go up?

This page does not forecast Simulations Plus, Inc.'s stock price. What it shows instead: the stock price is $18.50. Nobody can reliably say which way a price will move, and this site does not try (as of 5 October 2026).

Is Simulations Plus's profit real cash?

Yes, over the last 3 years, 164% of Simulations Plus, Inc.'s reported profit came in as cash from operations. The latest year was lower at -28%, so the trend is worth watching. In FY25, operating cash was $18.1 M against reported profit of −$64.7 M.

Most of that cash then goes into building new capacity. These are yearly figures (as of 5 October 2026).

Where is Simulations Plus in its business cycle?

Simulations Plus, Inc.'s FY25 operating margin was 9.1%, against a 5-year range of 9.1% to 28.2%: the low end of its own range, which is often where recoveries start. The latest quarter was 22.8%.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 October 2026).

What could break the Simulations Plus story?

The main question: the share price moved +15.5% in a year while yearly earnings per share moved −757.1%. The difference came from the market paying a higher multiple.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 October 2026).

Is Simulations Plus a stock worth studying right now?

What the numbers show: Simulations Plus, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 October 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 5 October 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.